Scarica l'app Stockscreener
0.334
3.94%
-0.0137
Pre-mercato:
.34
0.006
+1.80%
IGC Pharma Inc Borsa (IGC) Ultime notizie
IGC Pharma Increases Authorized Shares to 600 Million - TipRanks
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - The Joplin Globe
IGC Pharma (IGC) spotlights Alzheimer's cannabinoid trial amid Schedule III talks - Stock Titan
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - pharmiweb.com
Can IGC Pharma Inc. stock test all time highsEarnings Recap Report & Fast Gaining Stock Reports - Newser
Why IGC Pharma Inc. (IGS1) stock is favored by hedge fundsQuarterly Performance Summary & Fast Moving Trade Plans - Newser
Why institutional investors increase stakes in IGC Pharma Inc. (IGS1) stockInflation Watch & Fast Entry Momentum Alerts - Newser
Why IGC Pharma Inc. (IGS1) stock attracts HNW investorsBuy Signal & Weekly Breakout Watchlists - Newser
Is IGC Pharma Inc. (IGS1) stock worth holding before Fed meeting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
IGC Pharma (NYSE American: IGC) registers 978,235 shares for stockholder resale - Stock Titan
Is IGC Pharma Inc. (IGS1) stock a top pick for value investorsJuly 2025 Review & Weekly Watchlist for Consistent Profits - Newser
Is IGC Pharma Inc. stock worth holding before Fed meetingWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser
Will IGC Pharma Inc. stock beat value stocksGDP Growth & Safe Capital Growth Plans - Newser
IGC Pharma Publishes Caregiver's Guide on Alzheimer's Disease - GuruFocus
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Big News Network.com
Why IGC Pharma Inc. stock stays undervaluedMarket Volume Summary & Expert Curated Trade Setups - Newser
Will IGC Pharma Inc. (IGS1) stock beat growth indexesShare Buyback & Verified Trade Idea Suggestions - Newser
IGC Pharma (NYSE American: IGC) backs expert-led Alzheimer's caregiver guide - Stock Titan
How IGC Pharma Inc. stock reacts to weak economyWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
What drives IGC Pharma Inc stock pricePortfolio Allocation Tips & Buy Sell Signal Notifications - earlytimes.in
New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Fact - GuruFocus
IGC Pharma (IGC) Advances Alzheimer's Research with AI-Driven Ap - GuruFocus
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Tr - PharmiWeb.com
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Weatherford Democrat
IGC Pharma (NYSE: IGC) Uses MINT-AD AI to Map Socioeconomic Alzheimer’s Risks - Stock Titan
An analyst sees good growth prospects for IGC Pharma Inc (IGC) - Setenews
Will IGC Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Is IGC Pharma Inc. (IGS1) stock considered safe havenEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com
Is IGC Pharma Inc. (IGS1) stock undervalued after correction2025 Market Overview & Technical Pattern Based Signals - newser.com
Is IGC Pharma Inc. stock a contrarian opportunityWeekly Gains Report & Risk Controlled Swing Alerts - newser.com
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):